TAGLN2 and neoplasm: Surprisingly, exogenous introduction of a cell-permeable and ubiquitination site-mutated (K78R) recombinant transgelin-2 (dU-TG2P) into BMDCs significantly potentiated tumor regression in vivo, suggesting a potential use for transgelin-2 peptides in DC-mediated anticancer therapy.